Objective: To present an updated review and criticism of viral hepatitis A and B prevention by immunization. Summary of the findings: Viral hepatitis prevention is an enormous challenge to the public health systems of countries and the medical and scientific communities. Hepatitis viruses produce important morbimortality in the world, causing acute and chronic hepatic disease. There are highly efficient vaccines available on the market to prevent new infections by the A and B viruses. However, A and B viruses continue to be among the most commonly notified diseases preventable by vaccines. In this article, we discuss the vaccines used to prevent these infections, with the aim of expanding knowledge and the practice of prevention of these infectious diseases.
Introduction
Viral hepatitis is an important health problem in Brazil and the world. Notable discoveries and progress have been made over the last three decades, as regards pathogenesis, prevention and treatment. The development of vaccines to prevent these infections, by inducing active immunity against A and B hepatitis viruses, was one of the major scientific conquests. However, morbidity and lethality resulting from these diseases persist. In the USA, in 2003, 61 ,000 individuals were infected by the viral hepatitis A virus (HAV) and 73,000, by that of hepatitis B. 1 In Brazil, the Ministry of Health estimates that 15% of the population has been in contact with the hepatitis B virus (HBV) and that on an average around 60% of individuals present with anti-HAV antibodies. 2 The Pan American Health Organization (PAHO) estimates that over 90% of the population over the age of 20 years has been exposed to the virus, and assesses infection by HAV in Brazil to be approximately 130 new cases per 100 thousand inhabitants/year.
In 1992, the World Health Organization (WHO) recommended that all countries should introduce hepatitis B vaccine in routine pediatric programs by 1997. 3 Rather than prevent acute hepatitis, the purpose was to reduce chronic infection, frequently not apparent in children, but causing severe sequelae in adult life. About 80 to 90% of the world population live in countries where the prevalence of carriers is moderate (2-7%) or high (> 7%). 4 The first vaccine available for viral hepatitis prevention was against HBV, developed in the early 1980s, and made with human plasma. Afterwards, it was replaced with vaccines produced by the recombinant DNA technique. In Brazil, although the number of notifications does not reflect the true incidence of the infection, studies on seroprevalence for hepatitis A show that the national mean is around 65%. 5 Among the cases of viral hepatitis notified to the health services, approximately half are due to HAV.
In the United States, where home and sexual contact with infected persons was the main HAV transmission mode between 1996 and 2002, there was a reduction in the incidence of the disease, mainly in the group from 5 to 14 years of age. It was observed, however, that the incidence of HAV among persons that travel to endemic areas and men that have sexual relations with men has increased dramatically since 1995. 4, 6 The number of chronic virus B carriers in the world is estimated at 450 million, and at around 2 million in Brazil.
In the USA, although there was a large reduction in the incidence of acute hepatitis B, mainly in the group from 15 to 39 years of age, this continues to be the age group most affected by acute infection. 6 Individuals that have multiple sex partners and are drug users continue to be the main transmitters of the disease in that country. 6 It is estimated that the risk of developing hepatocarcinoma is 100 times higher among HBV carriers, in comparison with those that do not have the virus, and that 15-20% of those that have HBV may die prematurely. 3 The reason for reviewing and expanding current knowledge and the recommendations about these vaccines is based on the high rates of viral hepatitis A and B in some regions of the country, and the persistence of insufficient protection of individuals that become infected and propagate viral infecction. 1, 4, 6, 7 The objective of this article is to review hepatitis A and B prevention by vaccination, describe the properties of the vaccines, review clinical studies and their results and, finally, discuss the impact of introducing these vaccines.
Hepatitis A vaccine
In 1978, Provost & Hillemann, 8 in animal studies, demonstrated the ability of a vaccine inactivated by formalin to produce protective antibodies against HAV.
The possibility of cultivating the virus in cell cultures made it possible to manufacture large quantities of the vaccine against HAV, and the use of sensitive immunoassays and antibody neutralizing tests made it feasible to recognize the immunogenic capability of the different vaccines.
Fortunately the HAV virus exists all over the world with one single serotype, with a small degree of antigenic variation. 9 Present evidence has shown that immunity, either acquired naturally or by inactivated vaccines, protects against the different virus A strains. 9 The antibodies resulting from the vaccine, although lower in number, have the same neutralizing capacity as the antibodies naturally produced after infection. Although there is genetic heterogeneity among the different virus A strains, it would appear that there is no significant variation in the conformation of the epitope that determines virus neutralization, as polyclonal antibodies neutralize the virus of all the genotypes. 9, 10 As HAV immunity is mainly mediated by antibodies, the vaccine needs to present the epitopic conformation to the individuals immune system in a sufficient dose to induce the formation of neutralizing antibodies. To confer lasting protection, the levels of these antibodies must be considerably higher than those acquired with immunoglobulins.
The following safe and highly efficient vaccines, Table 1. 2 Although the vaccine doses and formulations are different, both the number and the dose intervals are the same: they must be administered in 2 doses, with a 6-month interval between them. Still limited data indicate that if this interval between the 1st and 2nd dose cannot be observed, the antibody concentrations will not be compromised to a major extent. Generally speaking, considering the excellent results obtained with the vaccine, there is no need for post-vaccinal tests.
The HAV vaccine is derived from viruses adapted in cell cultures, afterwards purified and inactivated with formalin and finally adsorbed to an adjuvant, generally aluminum hydroxide.
Clinical studies, based on millions of doses administered to healthy persons, demonstrated the protective efficacy and tolerability of the inactivated vaccines. 11, 12 Even vaccination schemes with 1 dose only of the vaccine provide immediate protection. 13 The anti-HAV antibody levels after one single dose of the vaccine are greater than vaccine. In addition, the frequency of adverse effects, except fever, diminished with successive doses. 13, 17 Immune response to infection by HAV is complex, but clearly involves cellular and humoral immunity, cellular Van Herck et al. 18 developed mathematical models to assess the development of anti-HAV antibodies, after administration of 2 inactivated vaccines (Havrix and Avaxim). The two vaccines showed similar results; when the antibody levels were higher than 20 mUI/mL, they remained for at least 10 years after completing the vaccination scheme. It should be remembered that responsive individuals with decreasing and even undetectable titres may continue to be protected through the anamnestic anti-viral response. 11, 13 In these vaccinated individuals, antibodies were detected on re-exposure to the antigen, thus confirming the immunologic memory. 19 Although the duration of vaccine induced protection has not been well determined, the mathematical models suggest that protective antibody levels may persist for 24 to 47 years after the second dose, administered 6 to 12 months after the first. 20 Cederna et al. 19 related to the circulating antibodies, and thus only to humoral immunity. 18, 19 Over the last few years the incidence of viral hepatitis A in the United States has shown an important decline with the use of the vaccine, from 12 cases/100,000 individuals in 1995 to 3.1 cases/100,000 in 2002. 4, 6, 21 This reduction was higher in the states where vaccination of all children over the age of 2 years was recommended by the Advisory Committee for Immunization Practices (ACIP). As from 1999 a decrease of 67% from 7.2 cases/100,000 to 2.4
cases/100,000 in 2002 4, 6 was observed. This reduction was similar in 6 other North American states, where the vaccine was recommended, although not mandatory 69% reduction, from 6.4 cases/100,000 to 2 cases/ 100,000 in 2002. 4, 6 In the other 33 states, where the HAV vaccine HAV was not established as routine, the reductions in incidence of the disease were much lower 35%, from 3.4 cases/100,000 in 1999 to 2.2 cases/100,000 in 2002.
A great reduction in hepatitis A cases occurred in the age group from 5 to 14 years between 1996 and 2002. 4, 6 Recently there was an important change in the seroconversion rates [28] [29] [30] [31] (Table 2) . The response of patients with decompensated chronic hepatic disease is known to be lower, with lower antibody levels and lower seroconversion rates, when compared to those with compensated disease. 6, 17, 33, 34 Response to the vaccine was recently assessed in Porto Alegre, in children with Down syndrome and chronic hepatopathies. [35] [36] [37] Satisfactory seroconversion results were obtained, but with lower antibody titres than those in normal children in the same age group. The results are given in Tables 2 and 3 95.2%). 6, 17, 30 Nebbia et al. 38 studied children and adolescents of up to 16 years of age with cirrhosis and observed an adequate response to HAV vaccine. The results are given in Table 3 .
Impact of anti-HAV vaccination
The epidemiologic status of a certain region is not static, it presents changes due to various factors. Among them, perhaps the most important is change in socioeconomic and hygiene conditions. 39, 40 In some Latin American regions, a decrease in cases in younger age groups has been noted over the last few years, with a shift in the seroprevalence curve of the infection to the adult age group. 41 This basically occurs as a result of the improvement in the populations sanitary and socioeconomic conditions.
The existence of vaccine against HAV makes it feasible to substantially reduce the incidence of the disease, eliminate virus transmission and, eventually, even to eradicate the infection. Reduction in the incidence of the disease will be attained through promoting high levels of immunity in persons who serve as reservoirs of the virus.
This highly immunized population will diminish the incidence of HAV and, presumably, virus circulation. respectively. 44 Up to now no large scale anti-HAV vaccination strategies have been established in Latin American countries. One the one hand, in the highly endemic regions, it is almost impracticable to identify the groups at risk for acquiring the disease; and on the other, the high cost of vaccine makes it difficult to extend this benefit to the entire population. [45] [46] [47] Israel was the first country to adopt universal vaccination for children at 18 and 24 months of age in June 1999, and the results were excellent. 48 A very recent analysis of the impact of this program, 5.5 years after it began, reveals that an important decline has been observed in the incidence of the disease in all age groups, with 90%
coverage for the first dose and 85% for the second. 48 The authors suggest that universal immunization programs designed for pre-school children are highly effective and feasible. 48 Another recent study conducted in Australia also revealed the impact of vaccination in indigenous children
(two doses applied at 18 and 24 months). 49 Although the program had been designed to protect the high risk population, there was a rapid and important decline in the notification rates and the benefit was soon extended to other groups in the community. 49 Children at pre-school age must be the main focus of immunization strategies, because of their critical role in virus transmission. 21, [45] [46] [47] 50 As has been demonstrated by different studies, the efficient way to diminish incidence of the disease and even eradicate the infection is mass vaccination of children. There are, however, many barriers to this measure being adopted, among them: the growing number of vaccinations in childhood, other public health priorities, the cost of vaccine and the reduced number of cost-effectiveness studies of this strategy for our country.
Until this happens, the strategy applied in our country will continue to be that of preventing HAV in risk groups, respecting hierarchy as regards the destination of available public resources. While mass vaccination does not occur, we will continue to see patients develop severe hepatitis conditions, including the fulminant form. Recently, in a multi-centric study, we demonstrated that approximately
40% of hepatic insufficiency cases in children in Latin
America are due to hepatitis A. 51 
Hepatitis B vaccine
Up to the present time, hepatitis caused by the virus B is one of the main causes of hepatic disease in the world. (anti-HBs) are higher than 10 mUI/mL. 6 In the pediatric age group, the protection levels attained with the vaccine are 16% to 40% after a single dose, 80% to 95% after two doses and 98 to 100%, after three doses. 6, 54 In premature newborns, weighing less than 2 kg, the antibody levels are lower and the seroconversion rates smaller. A recent study conducted by Sadeck & Ramos, 56 about response to vaccination in pre-term newborns, showed a similar response to that in full term babies. However, in 25% of those with birthweight equal to or lower than 1,500 g, the response was not satisfactory. The authors indicated the need to assess seroprotection after the third dose of the vaccine or administer 1 booster dose at 12 months. 56 Among adolescents and adults, the antibody response rates are 20% to 30% after one dose, 75% to 80%
following two doses and 90% to 95% after three doses. 6 The assurance of the vaccines long-term efficiency is due to the anamnestic anti-HBs response. 4, 6, 7 The factors that diminish hepatitis B vaccine immunogenicity, in addition to inadequate care of the material (cold chain, for example) include: Age over 40 years, male sex, smoking, obesity and immunologic deficiency. 4, 6, 7 Duval et al., 57 Immunity duration in low risk children born to HBsAg negative mothers, vaccinated soon after birth, is still under discussion. 51 In these individuals, the risk could reappear during adolescence and the beginning of sexual life.
Petersen et al. 52 studied post-vaccination protection duration in high and low risk children of 4 to 13 years of age, vaccinated at birth. They observed that in the majority of cases, anti-HBs disappears at around 5 years of age, although a large number of them showed immunologic memory. In a third of these children, there was failure in the anamnestic response after a booster dose. On the other hand, Gong et al., 58 in China, assessed vaccination protection 3 to 12 years after vaccination at birth in 2,419 children, and concluded that the protective effects of the recombinant vaccine were significant 12 year later. The authors believe that the vaccine booster is not necessary in these children, since the HBsAg positivity rate in this population did not rise in later years. 58 Zanetti et al., 59 in Italy, analyzed immunity duration and the eventual need for a booster dose in 1,212 children and 446 air force recruits, after 10 years of implementing vaccination in nursing infants and adolescents in that country. They concluded that a strong immunologic memory persists for over 10 years after a primary course of immunization, and booster doses of the vaccine are unnecessary.
There is no doubt that immunoprophylaxis has the greatest cost-benefit for global control of infection by the virus B and its complications. 60 Passive immunization by hyper immune immunoglobulin (HBIG), provides temporary immunity at a high cost. Therefore, the most efficient strategy has been universal immunization programs to prevent both perinatal and horizontal transmission of infection by the hepatitis B virus.
The strategies indicated for universal immunization and the risk groups are presented as follows, as well as in Table 6 
HVB vaccine in special groups
It is generally known that the immunogenic capacity of vaccine is lower in certain groups of persons, among them: The elderly, obese, alcoholics, individuals submitted to antiblastic chemotherapy and immunodepressed patients. To improve response to vaccine, some strategies could be implemented. Kappor et al., 66 for example, used the granulocyte formation stimulating factor with encouraging results.
Premature newborns, weighing less than 2 kg at birth, should receive the first dose of the vaccine when the child is 1 month old. 22 Response to the vaccine, under this circumstance, is comparable to that of full term children, irrespective of the birthweight and gestational age. 22 Hepatitis B vaccine immunogenicity is low in patients infected with HIV, but the ideal vaccination scheme for these patients is still undefined. of the immune system could lead to a reduction in the capacity to respond to the vaccine. 67 With regard to chronic hepatopathies, when they present light or moderate disease, vaccination results are similar to those of healthy adults, attaining up to 100% seroconversion in some studies. 6, 17, 33 In patients with cirrhosis due to alcohol, seroconversion rates are low, ranging from 12% to 75% and in patients on liver transplant lists they are even lower, ranging between 7% and 55%. 6 Vaccine against HBV is recommended at higher doses in patients on hemodialysis. Seroprotection has been documented in 64% of patients with a normal vaccination scheme of three doses, and 86% in those that received an extra dose of vaccine. 4, 6 The response basically depends on the doses used and the stage of the renal disease at which the patient was vaccinated. Those that present creatinine over 4 mg/dL, and are on dialysis, respond in a worse manner than those with more moderate renal insufficiency. Chronic nephropathies must be vaccinated as early as possible and it is advisable to institute vaccination before submitting them to dialysis. In these patients, annual antibody level (anti-HBs) monitoring is indicated, as well as a booster dose when these levels are below 10 mUI/mL. 4, 6 Impact of anti-HVB vaccination Another fundamental measure for reducing the incidence of acute virus B hepatitis was the recommendation to test all pregnant women for HBsAg and to protect the newborns of all infected mothers with vaccine and immunoglobulin. 4, 6, 21 The Ministry of Healths National Hepatitis Program is undertaking a series of strategic measures to broaden knowledge related to hepatitis in Brazil. 2 One of the aspects that is receiving special attention is serologic screening of HBsAg in pregnant women. The importance of hepatitis B during gestation is mainly because of the high potential of transmission from mother to newborn and the tendency of hepatitis B to become chronic (70-90%) when contact occurs at an early age.
An enquiry recently carried out to assess gynecologists and obstetricians knowledge with regard to various aspects of hepatitis B revealed an alarming situation. 68 Approximately half of the 262 professionals interviewed asked for the marker (HBsAg) for mothers in the first trimester of gestation, although it is known that in order to protect the newborn adequately, screening must be done in the third trimester. On the other hand, the large majority of the professionals (group at risk for hepatitis B)
had been vaccinated, but only 58% had performed antiHBs. 68 The scheme proposed by the Ministry of Health is represented in Figure 2 .
In the United States, the cumulative effect of the use of the hepatitis B vaccine has shown important reductions in the incidence of acute hepatitis B from 9.2 cases/ These reductions clearly show that universal vaccination programs are more efficient than vaccination in risk groups.
At present, the development of mutants as a result of vaccination programs is of concern in these high endemicity countries. The prevalence of surface antigen gene mutants, which may cause the vaccine to fail, is the current worry, as it increased gradually 5 to 10 years after the programs were instituted. Reduction in HVB infection rates after the universal vaccination programs started had a dramatic effect on the incidence of hepatocellular carcinoma in children in Formosa. The annual incidence of liver cancer diminished by 75%, from 0.52/100,000 in children born before July 1984 to 0.13/100,000 in those born after 1984. 72 If these rates continue to decline, there should also be a substantial decrease in hepatocellular carcinoma in adults in the near future.
Lastly, it is important to remember that in our country, hepatitis from the Delta virus is still highly prevalent in some areas of Eastern Amazonia. As this concerns a defective virus, the distribution of the infection is superimposed on that of hepatitis B. When protecting individuals against HBV, we are also preventing the specter of serious diseases, both of super-infection and co-infection, determined by the association of B and Delta viruses.
Final considerations
Infections caused by viral hepatitis A and B generate enormous problems related to morbidity and mortality, in addition to costs, not only with the diseases, but also by determining an increase in the number of liver transplants.
Instead of us continuing to think of hepatitis A and B as common diseases that affect our patients, we should perhaps face them now, as infections that can be eradicated from our country. HVB vaccination is already available to all children when they are born, for adolescents up to the age of 19, and for all risk patients in the public health service. HAV vaccine, not yet available in the public health system, should be indicated for patients with financial resources, as these persons form the largest susceptible group and are therefore at greater risk. It should be remembered that for risk groups, this vaccine is available in the public health system at the CRIE in Brazil.
Health professionals, the lay community, above all the parents and the media must be continually informed about the benefits and adequate use of the vaccines available in 
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